Gossamer Bio (GOSS) Total Liabilities (2018 - 2026)
Gossamer Bio (GOSS) posted quarterly Total Liabilities of $290.4 million for Q1 2026, up 1.24% year-over-year from $286.8 million in Q1 2025, and down 1.57% quarter-over-quarter from $295.0 million in Q4 2025.
Gossamer Bio (GOSS) Total Liabilities (2018 - 2026) Analysis & Trends
Gossamer Bio's Total Liabilities history runs 9 years deep, the most recent figure standing at $290.4 million for Q1 2026.
- In Q1 2026, Total Liabilities rose 1.24% year-over-year to $290.4 million; the TTM figure through Mar 2026 stood at $290.4 million (up 1.24% YoY), while the FY2025 annual figure was $295.0 million, up 3.22% from the prior year.
- Total Liabilities for Q1 2026 stood at $290.4 million, down from $295.0 million in the prior quarter.
- The five-year high for Total Liabilities was $296.7 million in Q3 2024, with the low at $232.6 million in Q1 2024.
- The 5-year median for Total Liabilities is $267.2 million (2022), against an average of $270.4 million.
- The sharpest annual moves came in 2022 and 2023: Total Liabilities advanced 25.73% in 2022, then decreased 8.94% in 2023.
- Gossamer Bio's Total Liabilities stood at $260.4 million in 2022, then slipped by 4.31% to $249.1 million in 2023, then advanced by 14.71% to $285.8 million in 2024, then increased by 3.22% to $295.0 million in 2025, then fell by 1.57% to $290.4 million in 2026.
- Business Quant data shows GOSS's Total Liabilities at $290.4 million in Q1 2026, $295.0 million in Q4 2025, and $291.2 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 7.18 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 10.02 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 1.62 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 4.20 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 4.00 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 4.20 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 1.35 Bn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 10.03 Bn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 3.22 Bn |
| 10 | Gossamer Bio | 50.34 Mn | -6.69 Mn | - | 170.90 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 170.90 Mn |
| Mar 31, 2026 | 290.38 Mn |
| Dec 31, 2025 | 295.01 Mn |
| Sep 30, 2025 | 291.15 Mn |
| Jun 30, 2025 | 287.03 Mn |
| Mar 31, 2025 | 286.84 Mn |
| Dec 31, 2024 | 285.80 Mn |
| Sep 30, 2024 | 296.74 Mn |
| Jun 30, 2024 | 291.92 Mn |
| Mar 31, 2024 | 232.64 Mn |
| Dec 31, 2023 | 249.15 Mn |
| Sep 30, 2023 | 243.31 Mn |
| Jun 30, 2023 | 244.55 Mn |
| Mar 31, 2023 | 248.36 Mn |
| Dec 31, 2022 | 260.37 Mn |
| Sep 30, 2022 | 267.19 Mn |
| Jun 30, 2022 | 262.31 Mn |
| Mar 31, 2022 | 264.52 Mn |
| Dec 31, 2021 | 222.19 Mn |
| Sep 30, 2021 | 217.23 Mn |